



## Altimune to Participate at Two Upcoming Investor Conferences

November 6, 2024 at 7:30 AM EST

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in the following investor conferences:

- **Guggenheim Inaugural Healthcare Innovation Conference** (Boston, MA)  
Monday, November 11, 2024  
*Fireside Chat at 11:30 a.m. Eastern Time*
- **UBS Global Healthcare Conference** (Rancho Palos Verdes, CA)  
Wednesday, November 13, 2024  
*Available for 1x1 meetings*  
*Fireside Chat at 9:30 a.m. Pacific Time*

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

### About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow [@Altimune, Inc. on LinkedIn](#)

Follow [@AltimuneInc on Twitter](#)

### Company Contact:

Vipin Garg  
President and Chief Executive Officer  
Phone: 240-654-1450  
[ir@altimmune.com](mailto:ir@altimmune.com)

### Media Contact:

Danielle Cantey  
Inizio Evoke, Biotech  
Phone: 619-826-4657  
[Danielle.cantey@inizioevoke.com](mailto:Danielle.cantey@inizioevoke.com)

### Investor Contacts:

Lee Roth  
Burns McClellan  
Phone: 646-382-3403  
[lroth@burnsmc.com](mailto:lroth@burnsmc.com)

Julia Weilman  
Burns McClellan  
Phone: 646-732-4443  
[jweilman@burnsmc.com](mailto:jweilman@burnsmc.com)

This press release was published by a CLEAR® Verified individual.



Source: Altimune, Inc